Targeting Cancer With Precision Engineered C’Dot Platform

Elucida Oncology, Inc., is a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy with its first-in-class, ultra-small nanoparticle C’Dot drug conjugate (CDC) platform.


From the October 29, 2014 cover of Science Translational Medicine. Illustration: V. Altounian, C. Bickel/ Science Translational Medicine. Reprinted with permission from AAAS.

Our Science

CDCs are designed to penetrate deeper into tumors and deliver a significantly higher payload compared to antibody drug conjugates (ADCs). This combined with greater avidity for the target antigen, longer retention in tumors with minimal systemic exposure due to rapid renal clearance confers unique Target or Clear® properties.

In preclinical studies, this has resulted in enhanced efficacy irrespective of antigen expression levels with reduced off-target toxicity, thereby potentially addressing the limitations of ADCs and other novel drug carriers.

Lead Programs

Elucida Oncology is focused on advancing our CDC pipeline to treat patients with complex cancers.  Our lead program is currently enrolling patients in a phase 1 clinical trial and we are advancing numerous pre-clinical programs for patients with both solid and liquid tumors.